bomedemstat
bomedemstat: developed by 1 company · 9 clinical trials tracked.
bomedemstat evidence translation
What we can confirm
9 tracked trials
What it means
What to watch
Prepared research question
How could bomedemstat → IMGO affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 2 study sponsors
Related indications
Development Pipeline (1)
| Company | Phase |
|---|---|
| Imago BioSciences, Inc. (IMGO) Polycythemia Vera; Essential Thrombocythemia | Phase 2 |
Clinical Trials (9)
Phase 2 Study to Assess the Safety and Efficacy of Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis
Primary endpoint: SVR35 at Week 24
A Phase 2/3, Randomized, Open-label, Active-comparator-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543) Versus Best Available Therapy in Participants With Polycythemia Vera Who Have an Inadequate Response to or Are Intolerant to Hydroxyurea
Primary endpoint: Clinicohematologic Response (CHR) Rate
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat (MK-3543) Versus Hydroxyurea in Cytoreductive Therapy Naïve Essential Thrombocythemia Participants
Primary endpoint: Durable Clinicohematologic Response (DCHR) Rate
A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study
Primary endpoint: Percentage of participants with one or more adverse events (AEs)
A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) Versus Best Available Therapy (BAT) in Participants With Essential Thrombocythemia Who Have an Inadequate Response to or Are Intolerant of Hydroxyurea
Primary endpoint: Durable Clinicohematologic Response (DCHR) Rate
A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Bomedemstat in Patients With Polycythemia Vera (PV)
Primary endpoint: Number of Participants With Adverse Events (AEs)
VenBom: A Phase 1 Study of Bomedemstat (IMG-7289), a Novel Inhibitor of Lysine-Specific Demethylase 1 (LSD1), in Combination With Venetoclax in Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Primary endpoint: Incidence of Treatment-Emergent Toxicity
A Multi-Center, Open Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Patients With Myeloproliferative Neoplasms (MPNs) Enrolled in a Prior Bomedemstat Clinical Study
Primary endpoint: Percentage of Participants Who Experience an Adverse Event (AE)
A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy and Pharmacodynamics of IMG-7289 in Patients With Essential Thrombocythemia
Primary endpoint: Number of Participants Who Experienced an Adverse Event (AE)
Frequently asked questions
Who is developing bomedemstat?
bomedemstat is being developed by Imago BioSciences, Inc..
How many clinical trials involve bomedemstat?
BioSniper tracks 9 clinical trials involving bomedemstat.